Yiqun Bai, Ph.D. - Profile and Investment Details

Investor Profile

Yiqun Bai, Ph.D. is a Venture Capital, Investor, Entrepreneurship Program based in Boston, Massachusetts, United States with a diverse investment portfolio that includes companies such as KSQ Therapeutics, Denali Therapeutics, Syros Pharmaceuticals, Incredible Foods, Inzen Therapeutics, Ohana Biosciences, T2 Biosystems, Tangent Medical Technologies, Kaleido BioSciences, Permeon Biologics, Kovio, Oasys Water, Editas Medicine, Tessera Therapeutics, Ring Therapeutics, Moderna Therapeutics, Omega Therapeutics, Cygnal Therapeutics, Sana Biotechnology, Seres Therapeutics, Agios Pharmaceuticals, Red Rock Biofuels, Tarveda Therapeutics, Receptos, Repertoire Immune Medicines, Generate Biomedicines, Codiak Biosciences, BlackDuck, Polatis, Seventh Sense Biosystems, Sigilon Therapeutics, Boragen, TARIS Biomedical, TransMedics, Selecta Biosciences, Quanterix, Visterra, Sesen Bio, Inc., CiBO Technologies, medidametrics, Rubius Therapeutics, Axcella, Senda Biosciences, Foghorn Therapeutics, Evelo Biosciences, Inari, Joule Unlimited Technologies, Cellarity, WikiCell Designs, Avedro, Indigo, EcoSense Lighting, Valo Health, Invaio Sciences. Over time, Yiqun Bai, Ph.D. has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Yiqun Bai, Ph.D. is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Enterprise, Medical Testing, GreenTech, Women Led, Life Science, Artificial Intelligence (AI), Biotech, Social Entrepreneurship, EnergyTech, Synthetic Biology, Medical Device, Healthcare, Biotechnology, Hispanic / Latinx Founded, Natural Resources, Market Research, AgTech, Agriculture, Health Diagnostics, Farming, Innovation Management, Chemicals, Medical, Therapeutics, Media and Entertainment, Machine Learning, Pharmaceuticals, Sustainability, Biopharma may find it worthwhile to explore potential connections with Yiqun Bai, Ph.D., as their portfolio suggests a familiarity and interest in this area.

Understanding Yiqun Bai, Ph.D.’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.